Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1696743

	registered interest
	date	18/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Nurses: Schools
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many full-time equivalent qualified school nurses are working in a public health-commissioned (a) school nursing service, (b) zero to 19 service and (c) five to 19 healthy child programme in each local authority area.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	19035
	answer	answer is ministerial correction date of answer 04/04/2024 answer text <p>Since April 2013, local authorities have held responsibility for commissioning public health services for school-aged children. These services may be commissioned from a range of providers both inside and outside of the National Health Service. NHS England publishes monthly workforce data which includes information on the number of school nurses directly employed by NHS trusts and other core NHS organisations in England. This data will not represent the total number of school nurses delivering local authority commissioned services, as it will excludes places where services are commissioned outside of the NHS. It is not possible to identify the specific service or programme that these staff are working within.</p><p>While data is not available at a local authority level, the following table shows full-time equivalent (FTE) school nurses working within NHS trusts and other core organisations in England by Government Office Region, as of November 2023:</p><table><tbody><tr><td><p>Government Office Region</p></td><td><p>FTE School Nurses</p></td></tr><tr><td><p>East Midlands</p></td><td><p>140</p></td></tr><tr><td><p>East of England</p></td><td><p>161</p></td></tr><tr><td><p>London</p></td><td><p>325</p></td></tr><tr><td><p>North East</p></td><td><p>55</p></td></tr><tr><td><p>North West</p></td><td><p>434</p></td></tr><tr><td><p>South East</p></td><td><p>291</p></td></tr><tr><td><p>South West</p></td><td><p>81</p></td></tr><tr><td><p>West Midlands</p></td><td><p>286</p></td></tr><tr><td><p>Yorkshire and The Humber</p></td><td><p>207</p></td></tr></tbody></table> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 04/04/2024 10:58:19 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1688273

	registered interest
	date	07/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions she (a) has had and (b) plans to have with (i) brain tumour research charities and (ii) other organisations working to secure UK access to (A) Vorasidenib and (B) other new drugs for cancers of unmet need.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	13599
	answer	answer is ministerial correction date of answer 19/02/2024 answer text <p>Department ministers and officials regularly meet with charities and other organisations working to improve outcomes for patients with cancer, including brain tumours, through access to new medicines.</p><p>The National Institute for Health and Care Excellence (NICE) makes recommendations on whether all new medicines should be routinely funded by the National Health Service based on an assessment of their costs and benefits and aims to publish guidance as close as possible to licensing. NICE engages with stakeholders, including charities, in the development of its recommendations. NICE is currently developing guidance for the NHS on the use of Vorasidenib.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 19/02/2024 09:35:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1687858

	registered interest
	date	06/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to (a) monitor the availability, (b) notify relevant stakeholders of shortages and (c) help ensure adequate supply of (i) Victoza and (ii) other medications for patients with diabetes.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	13302
	answer	answer is ministerial correction date of answer 13/02/2024 answer text <p>We are aware of global supply issues with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) including Victoza (liraglutide), which are licensed for treating patients with type 2 diabetes. We have issued guidance in the form of a Medicine Supply Notification, addressing all GLP-1 RAs advising healthcare professionals on how to manage patients requiring these medicines. Further guidance has been issued through a National Patient Safety Alert which provides further background and clinical information and actions for providers. This guidance was futher updated on 3 January 2024.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed to treat type 2 diabetes should only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland have also issued a joint statement stressing the importance of health and care professionals meeting regulatory standards in relation to these medicines. We have also added some of these products to the list of medicines that cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of these medicines for UK patients, for example by asking suppliers to expedite deliveries. Supplies of Rybelsus (semaglutide) have been boosted to support demand from new patients with type 2 diabetes, alongside patients switching from Victoza injections.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 13/02/2024 17:54:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1685425

	registered interest
	date	29/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Department of Health and Social Care: Environment Protection
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, which policies under each arms length body reporting to their Department fall within the scope of the Environmental principles policy statement, published on 31 January 2023.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	11755
	answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>The duty does not require us to maintain a comprehensive list of policies within scope of the duty. The duty applies to all policies made from 1 November 2023, whether developed by a central department or an arm’s length body, which are made by Ministers of the Crown; and not covered by the exemptions for the armed forces, defence or national security, taxation, spending or the allocation of resources within Government.</p><p> </p><p>The environmental principles policy statement provides further information on what is considered policy in scope of the duty. Examples include strategies and frameworks.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/02/2024 13:41:30 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1684482

	registered interest
	date	23/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Paxlovid
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of extending the eligibility criteria for Paxlovid to include people who are full-time carers to mitigate the risk of long covid.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	11045
	answer	answer is ministerial correction date of answer 30/01/2024 answer text <p>The Department has made no such assessment, as the National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations on whether medicines can be recommended for routine use on the National Health Service. NICE’s recommendations are based on a thorough assessment of the available evidence and developed through a rigorous process that includes extensive engagement with stakeholders.</p><p>NICE published guidance in March 2023 that recommends Paxlovid for patients at highest risk of developing serious illness from COVID-19. Paxlovid is now routinely available to NHS patients in line with NICE’s guidance. NICE issued final draft guidance on 11 January 2024 that expands its recommendation of Paxlovid to include other higher risk groups, including people aged 70 years and over, or with a body mass index of 35 or more, diabetes, or heart failure.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 30/01/2024 16:24:49 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1680855

	registered interest
	date	09/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Syringes: Standards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the US Food and Drug Administration safety communication Evaluating Plastic Syringes Made in China for Potential Device Failures, issued on 30 November 2023, whether her Department is undertaking a similar evaluation of syringes.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	8724
	answer	answer is ministerial correction date of answer 16/01/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is aware of the issues raised by the US Food and Drug Administration (FDA) concerning quality control and design problems with plastic syringes manufactured in China. Whist the MHRA works on the basis that CE or UKCA marked plastic syringes originally produced in China are in use within the United Kingdom healthcare system, one of the main suppliers of plastic syringes into the UK healthcare system, Becton, Dickinson and Company, has confirmed that their products are not affected by this issue.</p><p>Medical device safety issues may affect different global regions to varying extents. Whilst awareness and active information exchange between regulators is critical to focus national investigations, regulatory action is taken based on UK relevant evidence. Device safety corrective actions communicated via so-called Field Safety Notices (FSNs) related to the specific problems highlighted in the FDA alert have not been issued in the UK. FSNs issued in the UK are available at the following link:</p><p><a href="https://www.gov.uk/drug-device-alerts" target="_blank">https://www.gov.uk/drug-device-alerts</a></p><p>The MHRA is an active member of the International Medical Device Safety group. Representatives of regulatory authorities across the world meet on a regular basis to discuss emerging safety issues related to medical devices. The current issue was identified and MHRA are closely monitoring the situation. At this stage, there is insufficient evidence to justify actions against specific manufacturers of these products supplying into the UK.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/01/2024 09:48:35 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1678981

	registered interest
	date	19/12/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Primary Health Care: Sussex
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will provide NHS Sussex Integrated Care Board with the additional £8m funding required to pay for the projected increase in demand in primary care for Locally Commissioned Services for this financial year.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	7541
	answer	answer is ministerial correction date of answer 08/01/2024 answer text <p>The Department sets NHS England’s budget, with funding increasing to £162.5 billion in 2024/25.</p><p>NHS England is responsible for allocating healthcare resources to integrated care boards (ICBs) to meet the healthcare needs of their populations. ICBs then decide how that funding is spent within the local integrated care system. Allocations are determined using an independently recommended ‘weighted capitation’ formula to produce a target allocation or ‘fair share’, including for primary care, which accounts for population size.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 08/01/2024 10:47:36 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1673608

	registered interest
	date	28/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Prescriptions: Fees and Charges
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 23 November 2023 to Question 1512 on Prescriptions: Fees and Charges, what percentage of prescriptions are exempt from charges due to (a) Prescription Prepayment Certificates and (b) other reasons.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	4128
	answer	answer is ministerial correction date of answer 05/12/2023 answer text <p>The NHS Business Services Authority collects data on the number of prescription items that are exempt from charges. 5% of prescription items are paid for at the point of dispensing. 95% of prescription items are exempt from charges, and within this figure 3% are covered by a Prescription Prepayment Certificate (PPC). The remaining 92% includes every item with an exempt category or “unknown” exemption category so may also include some PPC exemptions.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 05/12/2023 09:57:17 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1671929

	registered interest
	date	21/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Pay
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to pay (a) nurses and (b) other healthcare and NHS staff for the extra hour they spend on shift when the clocks go back.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	2848
	answer	answer is ministerial correction date of answer 27/11/2023 answer text <p>Most nurses and other healthcare staff that are directly employed by National Health Service organisations are covered by national terms and conditions of service. These national terms and conditions do not make specific provisions, including pay provisions, for shifts that cover the period when the clocks change twice a year. This is therefore a matter for NHS organisations to determine locally, taking steps to ensure that consistent approaches are taken.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/11/2023 16:20:17 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas